

type of report	Current report
number	58/2013
company	PHARMENA

Share capital increase of Cortria Corporation

The Management Board of PHARMENA S.A. informs that on 13th August 2013, the Issuer increased share capital of subsidiary company Cortria Corporation by 1,000,000 USD (through the issue of 10,000 new shares). The share capital increase is financed from the Issuer's own funds obtained from the issue of series D shares.

The goal of the share capital increase is to finance:

- a) phase II clinical trials ("Proof of Concept") of innovative anti-atherosclerosis medicinal product (1-MNA),
- b) current operations of Cortria (patent fees, legal services, patent services).

The objective of phase II clinical trials (on people) of anti-atherosclerosis medicinal product (1-MNA) is to confirm its efficacy and absence of adverse side effects with increased doses. The research will be conducted by Cortria Corporation in Canada.

Cortria Corporation is a private pharmaceutical company with registered headquarters in Boston, Massachusetts, USA, which conducts clinical trials focusing on developing safe and well-tolerated medicinal products for the treatment of cardiovascular diseases, particularly atherosclerosis.

The information is made public due to the fact that the goal of share capital increase of Cortria Corporation is to finance phase II clinical trials of innovative anti-atherosclerosis medicinal product. According to the Management Board of PHARMENA S.A., this increases the possibility of commercialisation of the project. Potential revenue resulting from the commercialisation of anti-atherosclerosis medicinal product may have significant influence on the Issuer's financial and economic situation.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1)".

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska - Vice President of the Board